# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Dan Brennan maintains GeneDx Hldgs (NASDAQ:WGS) with a Buy and raises the price target from $14 to $24.
BTIG analyst Mark Massaro maintains GeneDx Hldgs (NASDAQ:WGS) with a Buy and raises the price target from $15 to $19.
GeneDx Hldgs (NASDAQ: WGS) raises FY2024 sales outlook from $220.00 million-230.00 million to $235.00 million-245.00 million.Ge...